Tirzepatide (Mounjaro): Research, Mechanism & Current Evidence

What is Tirzepatide?

Tirzepatide is a synthetic molecule that imitates two gut hormones released after eating. It was the first compound of its kind to reach approval, and is sold as Mounjaro for type 2 diabetes and Zepbound for weight management in some markets.

Unlike most compounds in this database, tirzepatide has been through the full regulatory process and is backed by large published trials in tens of thousands of participants.

Status: Approved for type 2 diabetes and for weight management in the UK, US and EU.

What is Tirzepatide researched for?

The two largest research programmes are SURPASS, which studied blood sugar control in type 2 diabetes, and SURMOUNT, which studied body weight in obesity.

Further work has examined obstructive sleep apnoea, heart failure with preserved ejection fraction, and fatty liver disease.

• Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.
• Improvements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.
• Preferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.
• Superior HbA1c reduction of 1.5-2.4% in clinical trials.
• Improves insulin sensitivity across diverse populations.
• May help preserve and restore pancreatic beta cell function.
• 26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.
• Systolic and diastolic blood pressure reductions of 8-12 mmHg.
• Triglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.

How does Tirzepatide work?

Tirzepatide acts on two hormone pathways at once — the GIP and GLP-1 receptors. Both hormones are released by the gut after a meal and both increase insulin release when blood sugar is high.

The GLP-1 side slows stomach emptying and reduces appetite through signals to the brain. The GIP side is less intuitive: on its own GIP has a mixed reputation in metabolic research, but combined with GLP-1 activation it appears to add to the effect on body weight and insulin sensitivity. Why the combination works better than either alone is still an open research question.

Reported targets: GLP-1 receptor

What does the research show?

In SURMOUNT-1, published in 2022, participants without diabetes taking the highest dose lost around 21% of body weight at 72 weeks. In the SURPASS programme, tirzepatide produced larger reductions in HbA1c than the comparator treatments it was tested against, including semaglutide in SURPASS-2.

Nausea, diarrhoea and vomiting were the most frequently reported side effects, generally most pronounced while the dose was being increased.

Limitations of the current evidence

Head-to-head data exists against semaglutide but not against newer triple agonists such as retatrutide, so cross-trial comparisons should be treated cautiously.

Most trials ran for 40 to 72 weeks. Questions about what happens over many years, and about weight regain after stopping, are still being studied.

References

1. Tirzepatide Once Weekly for the Treatment of Obesity

   Jastreboff AM, Aronne LJ, Ahmad NN, et al. · The New England journal of medicine · 2022

   Landmark phase 3 trial: 15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks. Weight reduction of ≥20% achieved in 57% of 15mg recipients.

   Controlled clinical trial · PMID 35658024

2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

   Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021

   Tirzepatide was noninferior and superior to semaglutide 1mg for HbA1c reduction and weight loss in type 2 diabetes. The 15mg dose achieved nearly twice the weight loss of semaglutide.

   Early human study · PMID 34170647

3. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

   Nicholls SJ, Pavo I, Bhatt DL, et al. · The New England journal of medicine · 2025

   Tirzepatide was noninferior to dulaglutide for MACE (composite of CV death, MI, or stroke). Several secondary endpoints favored tirzepatide, including reduced all-cause mortality after 4-year median follow-up.

   PMID 41406444

4. Tirzepatide for Obesity Treatment and Diabetes Prevention

   Jastreboff AM, le Roux CW, Stefanski A, et al. · The New England journal of medicine · 2025

   Three years of tirzepatide resulted in sustained weight reduction of up to 19.7% (15mg) and 93% lower risk of progression to type 2 diabetes vs placebo (HR 0.07).

   PMID 39536238

5. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

   Packer M, Zile MR, Kramer CM, et al. · The New England journal of medicine · 2025

   Tirzepatide reduced the composite of CV death or worsening heart failure by 38% (HR 0.62) vs placebo over median 104 weeks. Improved health status scores and 6-minute walk distance.

   PMID 39555826

6. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

   Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025

   Head-to-head comparison: tirzepatide achieved 20.2% weight loss vs 13.7% with semaglutide at 72 weeks. Tirzepatide was superior for body weight and waist circumference reduction.

   PMID 40353578

7. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

   Malhotra A, Grunstein RR, Fietze I, et al. · The New England journal of medicine · 2024

   Tirzepatide significantly reduced AHI with resolution of OSA in approximately 50% of participants. Also reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure.

   Controlled clinical trial · PMID 38912654

8. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

   Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet (London, England) · 2023

   Controlled clinical trial · PMID 37385275

Common questions